Search PubMed⌕ Search

PubMed · 16290406

Two-dimensional colloidal aggregation: concentration effects.

Abstract

Extensive numerical simulations of diffusion-limited (DLCA) and reaction-limited (RLCA) colloidal aggregation in two dimensions were performed to elucidate the concentration dependence of the cluster fractal dimension and of the different average cluster sizes. Both on-lattice and off-lattice simulations were used to check the independence of our results on the simulational algorithms and on the space structure. The range in concentration studied spanned 2.5 orders of magnitude. In the DLCA case and in the flocculation regime, it was found that the fractal dimension shows a linear-type increase with the concentration phi, following the law: d(f)=d(fo)+aphi(c). For the on-lattice simulations the fractal dimension in the zero concentration limit, d(fo), was 1.451+/-0.002, while for the off-lattice simulations the same quantity took the value 1.445+/-0.003. The prefactor a and exponent c were for the on-lattice simulations equal to 0.633+/-0.021 and 1.046+/-0.032, while for the off-lattice simulations they were 1.005+/-0.059 and 0.999+/-0.045, respectively. For the exponents z and z', defining the increase of the weight-average (S(w)(t)) and number-average (S(n)(t)) cluster sizes as a function of time, we obtained in the DLCA case the laws: z=z(o)+bphi(d) and z'=z'(o)+b'phi(d'). For the on-lattice simulations, z(o), b, and d were equal to 0.593+/-0.008, 0.696+/-0.068, and 0.485+/-0.048, respectively, while for the off-lattice simulations they were 0.595+/-0.005, 0.807+/-0.093, and 0.599+/-0.051. In the case of the exponent z', the quantities z'(o), b', and d' were, for the on-lattice simulations, equal to 0.615+/-0.004, 0.814+/-0.081, and 0.620+/-0.043, respectively, while for the off-lattice algorithm they took the values 0.598+/-0.002, 0.855+/-0.035, and 0.610+/-0.018. In RLCA we have found again that the fractal dimension, in the flocculation regime, shows a similar linear-type increase with the concentration d(f)=d(fo)+aphi(c), with d(fo)=1.560+/-0.004, a=0.342+/-0.039, and c=1.000+/-0.112. In this RLCA case it was not possible to find a straight line in the log-log plots of S(w)(t) and S(n)(t) in the aggregation regime considered, and no exponents z and z' were defined. We argue however that for sufficiently long periods of time the cluster averages should tend to those for DLCA and, therefore, their exponents should coincide with z and z' of the DLCA case. Finally, we present the bell-shaped master curves for the scaling of the cluster size distribution function and their evolution when the concentration increases, for both the DLCA and RLCA cases.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Agustín E González, Francisco Martínez-López, Arturo Moncho-Jordá, Roque Hidalgo-Alvarez. 2002-02-15. Two-dimensional colloidal aggregation: concentration effects.. https://doi.org/10.1006/jcis.2001.7973

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗